Defence Therapeutics Inc (TSE:DTC) has released an update.
Defence Therapeutics Inc. reports a significant breakthrough with their second-generation ARM-002 anti-cancer vaccine, demonstrating an 80% complete response rate in a melanoma model when used alongside an immune-checkpoint inhibitor. The company highlights the vaccine’s potential for not only treating established tumors but also providing long-lasting immune memory to prevent cancer recurrence. Following promising in vivo results, Defence is expanding its research to include difficult cancers such as ovarian and pancreatic, with plans to pursue Phase I clinical trials.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
